PlenOptika: Vision Testing Goes Global

article image
ARTICLE SUMMARY:

Growth-Stage and Series A-ready PlenOptika has managed, with funding that’s largely undilutive, to launch and commercially scale a new portable autorefractor called QuickSee in 30 countries, addressing a global need for vision testing. While the company’s top goal was to improve access for people in low resource settings, its product is as accurate as more expensive autorefractors, making it attractive for both low and high income settings.

With a novel low-cost, accurate and hand-held autorefractor, designed from the ground up, PlenOptika Inc. brings vision testing to the remote aboriginal village, the optician’s office under the staircase in Grand Central Station, and the inner-city school, so children that need glasses don’t fall behind. The company thus addresses global health, health equity concerns in the US, changing delivery models for eye care, and a global shortage of refractionists, by providing its QuickSee technology to the trained professionals who determine the proper prescription for people with poor vision.

This article is restricted to subscribers only.

To continue reading, select one of the options below:

Existing Subscriber?

Sign In to continue reading.


Need Multi-User Access?

Gain access for your entire organization.

Get Quote Check to see if your company already has access

Subscribe to MedTech Strategist:

Actionable intelligence exploring the people, challenges, and opportunities impacting the global medtech community.

Subscribe to MedTech Strategist
Subscribe to ELITE Strategist

Become an ELITE Strategist and unlock access to both MedTech Strategist and MTS Market Pathways.

Subscribe to Elite

Questions?

We're here to help! Please contact us at: